R& D in the Pharmaceutical Industry: A World of Small Innovations

Juan-José Ganuza, Gerard Llobet and Beatriz Domínguez (beazamora@hotmail.com)
Additional contact information
Beatriz Domínguez: BBVA, 28046 Madrid, Spain

Management Science, 2009, vol. 55, issue 4, 539-551

Abstract: It is commonly argued that in recent years pharmaceutical companies have targeted their research and development (R& D) at small improvements of existing compounds instead of riskier drastic innovations. In this paper, we show that the bias in the pharmaceutical industry toward small innovations might be driven by the low sensitivity of the demand. In particular, small innovations get a proportionally larger reward because pharmaceutical firms target them at the inelastic segments of the demand. As a consequence, firms find it relatively more profitable to invest in small innovations. We also study the effect on R& D incentives of marketing strategies and regulatory instruments aimed at controlling pharmaceutical expenditure.

Keywords: health care; pharmaceuticals; innovation; marketing (search for similar items in EconPapers)
Date: 2009
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (12)

Downloads: (external link)
http://dx.doi.org/10.1287/mnsc.1080.0959 (application/pdf)

Related works:
Working Paper: R&D in the Pharmaceutical Industry: A World of Small Innovations (2006)
Working Paper: R&D in the pharmaceutical industry: A world of small innovations (2005)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:inm:ormnsc:v:55:y:2009:i:4:p:539-551

Access Statistics for this article

More articles in Management Science from INFORMS Contact information at EDIRC.
Bibliographic data for series maintained by Chris Asher (casher@informs.org).